Wuhan YZY Medical Science and Technology Co., Ltd.

Wuhan YZY Medical Science and Technology Co., Ltd. was established in July 2011, with individualized diagnosis and treatment of major diseases such as cardiovascular diseases and tumors as its strategic direction. It is a high-tech enterprise specializing in the research and development, production, and sales of individualized medical diagnostic products. The company has established multiple technology platforms including ARMS fluorescence quantitative PCR, multiplex fluorescence quantitative PCR, nucleic acid mass spectrometry, fluorescence in situ hybridization, and circulating tumor cell detection. It has independently developed and produced molecular diagnostic products guiding individualized medication for cardiovascular and cerebrovascular diseases, companion diagnostic products guiding tumor diagnosis and treatment, fluorescence in situ hybridization products, and circulating tumor cell detection products, providing clinical diagnostic evidence for precision medicine. The company has built a 2,000 m² R&D center and a 3,200 m² GMP-standard industrialized workshop, and has successfully developed over 160 genetic diagnostic products and multiple in vitro diagnostic devices, among which 17 molecular diagnostic kits have passed the NMPA Class III medical device registration review and been approved for marketing.
The company has been recognized as a High-tech Enterprise, a National Gene Testing Technology Application Demonstration Center, a Hubei Provincial Enterprise Technology Center, a Hubei Provincial Specialized, Refined, Distinctive, and Innovative "Little Giant" Enterprise, a National Intellectual Property Advantage Enterprise, a Hubei Provincial Intellectual Property Demonstration Construction Enterprise, a Hubei Provincial Third Batch Hidden Champion Cultivation Enterprise in Segmented Fields of Pillar Industries, a Wuhan "Enterprise Research and Development Center," one of the first batch of Wuhan "Thousand Enterprises, Ten Thousand Talents" Support Program enterprises, and a provincial, municipal, and district-level listed reserve "Golden Seed" enterprise. From 2016 to 2022, it was recognized as a "Gazelle Enterprise" of the East Lake High-tech Development Zone each year. The company won the First Prize of Shandong Provincial Science and Technology Progress Award and Hubei Provincial Science and Technology Progress Award in 2018 and 2020 respectively, and won the Second Prize of the 2020 Chinese Medical Science and Technology Award.
The company emphasizes innovative research and development, has applied for more than 110 patents, obtained more than 70 patent authorizations, and has a research and development team of more than 60 people, many of whom have work experience overseas or in well-known industry enterprises. The company's products have successively entered more than 600 large and medium-sized hospitals across the country and received good market feedback, establishing an industry position in the field of individualized medicine.
YZY Medical adheres to the corporate mission of "tailoring to individual needs and treating according to individual conditions," and is determined to become a leading enterprise in the segmented field of individualized diagnosis and treatment.